Tissue repair & inflammatory signalling
Recovery is the most-researched peptide category and the one with the clearest mechanistic split: angiogenic signalling, actin remodelling, and inflammatory modulation are three separate pathways that get grouped under one commercial label. Canada Peptides stocks all three, plus the standard antioxidant. Priced and shipped in CAD, for laboratory and research use only.
BPC-157 is a synthetic pentadecapeptide studied around angiogenesis — new blood-vessel formation — and cytokine signalling. TB-500, a thymosin-β4 fragment, is studied around cell migration and actin remodelling. KPV is an α-MSH tripeptide studied on the anti-inflammatory side. Different pathways, which is why they appear together in protocols rather than as substitutes — the BPC-157 vs TB-500 comparison breaks the first two down directly.
Because BPC-157 and TB-500 are studied for complementary pathways, the BPC-157 + TB-500 blend exists as a single vial. The recovery stack protocol sets out how these are combined in research designs, and stacking fundamentals covers the general reasoning.
Glutathione is stocked here as the principal endogenous antioxidant — redox rather than repair, but routinely studied alongside this category. HGH Fragment 176-191 sits at the boundary with metabolic; it is a C-terminal fragment of growth hormone studied around lipolysis rather than tissue repair.
Subcutaneous administration dominates the research protocols in this category. Dosing math, reconstitution 101 and subcutaneous injection technique cover the handling; compound-specific figures are on each product page and in the BPC-157 dosage and TB-500 dosage write-ups. Research context only — not a dosing recommendation for human use.
Glutathione side effects — what the research reports
Glutathione side effects by evidence tier: what oral, intravenous, intranasal and inhaled trials recorded, the regulatory alerts on unapproved IV use, and why the vial matters as much as the molecule.
KPV side effects — what the research reports
KPV side effects by evidence tier: no human safety data exists, what the mouse colitis and skin studies did and did not look for, mechanistic considerations, purity as a confound and Canadian status.
KPV dosage — research dosing notes
What the literature reports about KPV dosage: the oral, intraperitoneal and topical amounts used in mouse colitis and skin models, why there is no human dosing data, and 10 mg vial arithmetic.
TB-500 side effects — what the research reports
TB-500 side effects, separated by evidence tier: what the human thymosin β4 trials actually recorded, what uncontrolled self-report adds, and the gaps neither covers.
Glutathione dosage — research dosing notes
What the literature reports on glutathione dosage: the ~14-minute intravenous half-life, the 600 mg and 1,400 mg IV Parkinson's protocols, the six-month oral dose-response trial, and reconstitution math for a 600 mg vial.
BPC-157 dosage — research dosing notes
A literature review of BPC-157 dosage: the animal dose ranges actually studied, the measured pharmacokinetics in rats and dogs, and why no human dose has been established. Research use only.
Research & educational use only. This page is informational and does not constitute medical advice or a therapeutic claim.

Canada Peptides
HGH FRAG 176-191 5MG
HGH FRAGMENT
$45.00·Recovery